AQR Capital Management
ADPT icon

AQR Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

AQR Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.78M Sell
362,916
-122,317
-25% -$1.87M ﹤0.01% 1725
2026
Q1 		$6.74M Buy
485,233
+16,793
+4% +$268K ﹤0.01% 1557
2025
Q4 		$7.61M Sell
468,440
-140,561
-23% -$2.29M ﹤0.01% 1339
2025
Q3 		$9.11M Buy
609,001
+176,598
+41% +$2.15M 0.01% 1136
2025
Q2 		$5.04M Buy
432,403
+122,131
+39% +$1.11M ﹤0.01% 1286
2025
Q1 		$2.26M Buy
310,272
+97,444
+46% +$749K ﹤0.01% 1537
2024
Q4 		$1.28M Sell
212,828
-49,136
-19% -$271K ﹤0.01% 1759
2024
Q3 		$1.34M Buy
261,964
+79,888
+44% +$348K ﹤0.01% 1705
2024
Q2 		$635K Buy
182,076
+129,201
+244% +$410K ﹤0.01% 1940
2024
Q1 		$168K Buy
52,875
+13,350
+34% +$51.7K ﹤0.01% 2282
2023
Q4 		$194K Buy
39,525
+26,313
+199% +$120K ﹤0.01% 2222
2023
Q3 		$72K Sell
13,212
-12,449
-49% -$82.3K ﹤0.01% 2262
2023
Q2 		$172K Sell
25,661
-15,962
-38% -$119K ﹤0.01% 2098
2023
Q1 		$360K Sell
41,623
-28,794
-41% -$254K ﹤0.01% 1883
2022
Q4 		$525K Buy
70,417
+30,856
+78% +$240K ﹤0.01% 1797
2022
Q3 		$282K Sell
39,561
-48,309
-55% -$455K ﹤0.01% 1962
2022
Q2 		$688K Sell
87,870
-75,420
-46% -$663K ﹤0.01% 1563
2022
Q1 		$2.27M Buy
+163,290
New +$2.57M ﹤0.01% 1112
2021
Q2 		– Sell
-18,721
Closed -$734K – 2215
2021
Q1 		$734K Buy
+18,721
New +$1.01M ﹤0.01% 1684

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

AQR Capital Management's ADPT Position: Q2 2026 in Review

AQR Capital Management reduced its Adaptive Biotechnologies (ADPT) stake by 25% in Q2 2026, selling an estimated $1.87M and leaving 362,916 shares worth $7.78M. The position accounts for ﹤0.01% of the portfolio, ranked #1725.

AQR Capital Management first reported a position in ADPT in Q1 2021 and has held it in 19 quarters since. The position peaked at $9.11M in Q3 2025. 300 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • AQR Capital Management held 362,916 shares of Adaptive Biotechnologies worth $7.78M as of Q2 2026.
  • AQR Capital Management sold 122,317 Adaptive Biotechnologies shares in Q2 2026, an estimated $1.87M.
  • Adaptive Biotechnologies made up ﹤0.01% of AQR Capital Management's portfolio in Q2 2026, its #1725 holding.
  • AQR Capital Management first reported a position in Adaptive Biotechnologies in Q1 2021 and has held it in 19 quarters since.
  • AQR Capital Management's Adaptive Biotechnologies position peaked at $9.11M in Q3 2025.
  • 300 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.